Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials.

Barnett H, Guhl M, Di Stefano F, Skanji D, Guilleminot S, Saint-Hilary G, Mozgunov P, Riviere MK.

Open source

DOI
10.1002/pst.70093
Published
2026-05-01
Container
Pharm Stat
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/pst.70093,
  title = {Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials.},
  author = {Barnett H and  Guhl M and  Di Stefano F and  Skanji D and  Guilleminot S and  Saint-Hilary G and  Mozgunov P and  Riviere MK.},
  year = {2026},
  journal = {Pharm Stat},
  doi = {10.1002/pst.70093},
  url = {https://doi.org/10.1002/pst.70093}
}

RIS

TY  - JOUR
TI  - Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials.
AU  - Barnett H
AU  -  Guhl M
AU  -  Di Stefano F
AU  -  Skanji D
AU  -  Guilleminot S
AU  -  Saint-Hilary G
AU  -  Mozgunov P
AU  -  Riviere MK.
PY  - 2026
JO  - Pharm Stat
DO  - 10.1002/pst.70093
UR  - https://doi.org/10.1002/pst.70093
ER  - 

APA

H, B., M, G., F, D. S., D, S., S, G., G, S., P, M., & MK., R. (2026). Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials.. Pharm Stat. https://doi.org/10.1002/pst.70093

Source records